We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+57.35%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.79B
AUM Growth
+$267M
Cap. Flow
-$147M
Cap. Flow %
-8.23%
Top 10 Hldgs %
60.02%
Holding
83
New
11
Increased
14
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$33.6M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$26.3M
3
CBAY
Cymabay Therapeutics
CBAY
+$23.5M
4
PCVX icon
Vaxcyte
PCVX
+$18.5M
5
EYPT icon
EyePoint Inc
EYPT
+$18.2M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$178M
2
PLRX icon
Pliant Therapeutics
PLRX
+$38.4M
3
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$26M
4
ETNB
89bio
ETNB
+$25.5M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$22.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.17%
2 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
76
DELISTED
Tourmaline Bio
TRML
– –
-90,065
Closed -$1.69M
VKTX icon
77
Viking Therapeutics
VKTX
$3.93B
– –
-1,050,000
Closed -$17.5M
XFOR icon
78
X4 Pharmaceuticals
XFOR
$429M
– –
-54,299
Closed -$1.42M
PSTX
79
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-1,000,000
Closed -$3.08M
ICVX
80
DELISTED
Icosavax, Inc. Common Stock
ICVX
– –
-643,825
Closed -$3.73M
RAIN
81
DELISTED
Rain Oncology Inc. Common Stock
RAIN
– –
-2,978,660
Closed -$26M
VECT
82
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
– –
-2,536,617
Closed -$21.6M
RXDX
83
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-1,655,000
Closed -$178M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, Cormorant Asset Management held 83 positions worth $1.79B, up 18% from $1.52B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Cormorant Asset Management withdrew a net $147M in Q2 2023, closing 19 positions and reducing 6 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $178M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Zentalis Pharmaceuticals worth $30.9M.

  • Cormorant Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 1,095,000 shares worth $30.9M.
  • Cormorant Asset Management added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $33.6M increase.
  • Cormorant Asset Management's biggest Q2 2023 reduction was 89bio, cutting an estimated $25.5M.
  • Cormorant Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $178M.
  • Cormorant Asset Management's ten largest holdings make up 60% of its $1.79B portfolio in Q2 2023.
  • Cormorant Asset Management opened 11 new positions and closed 19 in Q2 2023.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.79B.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.